Dupixent

News

FDA will decide in June on Dupixent for COPD

The FDA has started a priority review of Sanofi and Regeneron’s Dupixent as a treatment for chronic obstructive pulmonary disease (COPD), which could become the first new

News

FDA changes its mind and approves Takeda’s Eohilia

In its second attempt, Takeda has secured FDA approval for Eohilia, which becomes the first and only oral therapy in the US for eosinophilic oesophagitis (EoE).

News

Dupixent aces second COPD study, setting up FDA filing

With a second positive phase 3 trial in hand, Sanofi and Regeneron have said they plan to file for approval of Dupixent in chronic obstructive pulmonary disease (COPD), a

News

France reported to be probing Sanofi over Dupixent launch

France’s financial prosecutor has reportedly launched an investigation into Sanofi’s “financial communication” surrounding the launch of its biggest-selling drug Dupixent.

News

CHMP backs Almirall’s eczema therapy lebrikizumab

Almirall is within sniffing distance of EU approval for its IL-13 inhibitor lebrikizumab for atopic dermatitis, setting up a challenge to Sanofi and Regeneron’s market-lea

News

Apogee Therapeutics upsizes its IPO to $300m

In a small sign of a possible improvement in the sluggish biotech initial public offering (IPO) market, Apogee Therapeutics has said it expects gross proceeds of $300 mill

FDA will decide in June on Dupixent for COPD

FDA changes its mind and approves Takeda’s Eohilia

Dupixent aces second COPD study, setting up FDA filing

France reported to be probing Sanofi over Dupixent launch

CHMP backs Almirall’s eczema therapy lebrikizumab

Apogee Therapeutics upsizes its IPO to $300m

Agios mulls early FDA filing for sickle cell therapy

Using AI-driven synthetic personas to take your insights fur...

Dupixent

Editor's Picks